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Abstract We have pursued the hypothesis that the carbonyl
modification of proteins by glycoxidation and lipoxidation
reactions plays a role in atherogenesis. Human atherosclerotic
tissues with fatty streaks and uremic arteriosclerotic tissues were
examined, with specific antibodies, to detect protein adducts
formed with carbonyl compounds by glycoxidation or lipoxida-
tion reactions, i.e. advanced glycation end products (AGEs) or
glycoxidation products, such as carboxymethyllysine (CML) and
pentosidine, and lipoxidation products, such as malondialdehyde
(MDA)-lysine and 4-hydroxy-nonenal (HNE)-protein adduct.
All the four adducts were identified in the proliferative intima and
in macrophage-rich fatty streaks. If the carbonyl modification is
not a mere result but is a contributor to atherogenesis, inhibition
of glycoxidation and lipoxidation reactions might prevent
vascular tissue damage. We tested this hypothesis in rats
following balloon injury of their carotid arteries, a model
exhibiting a remarkable intimal thickening, which are stained
positive for all the four adducts. Oral administration of 2-
isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide
(OPB-9195), an inhibitor of both glycoxidation and lipoxidation
reactions, in rats following balloon injury effectively prevented
the intimal thickening. These data suggest a role for the carbonyl
modification of proteins by glycoxidation and lipoxidation
reactions in most, if not all, types of vascular tissue damage
(‘carbonyl stress’), and the usefulness of inhibitors of carbonyl
reactions for the treatment of vascular tissue damage.
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1. Introduction
Oxidative stress has been implicated in tissue damage asso-
ciated with several diseases including atherosclerosis. Oxida-
tion conspires with non-enzymatic glycation to form advanced
glycation end products (AGEs) [1], which lead to tissue dam-
age through the alteration of structure and function of matrix
proteins [2] and stimulation of pathogenic cellular responses
[3,4]. Among AGE structures are the glycoxidation products,
NO-carboxymethyllysine (CML) [5] and pentosidine [6]. Sev-
eral intermediate carbonyl compounds resulting from the ox-
idation of glucose have been identi¢ed as e⁄cient precursors
of CML and pentosidine, such as glyoxal, arabinose, methyl-
glyoxal, and glycolaldehyde [7^9], as well as dehydroascorbate
formed on oxidation of ascorbate [10,11].
Lipid peroxidation of polyunsaturated fatty acids, such as
arachidonate, yields other carbonyl compounds: some are
identical to those formed from carbohydrates [12], such as
glyoxal and methylglyoxal, and others are characteristic of
lipids, such as malondialdehyde (MDA) and 4-hydroxy-none-
nal (HNE) [13]. The latter carbonyl compounds produce lip-
oxidation products, such as MDA-lysine and HNE-protein
adduct.
We therefore hypothesized that under oxidative stress in
vascular lesions, carbohydrates, ascorbate, and polyunsatu-
rated fatty acids may be converted to carbonyl intermediates,
which, in turn, react with tissue proteins, leading to formation
of glycoxidation and lipoxidation products. In the present
study, in order to characterize carbonyl modi¢cation of pro-
teins by glycoxidation and lipoxidation reactions in vascular
lesions, we immunohistochemically examined human athero-
sclerotic tissues and arteriosclerotic tissues from uremic pa-
tients.
If the carbonyl modi¢cation is not merely a result of oxi-
dative stress but a contributor to atherogenesis, inhibition of
glycoxidation and lipoxidation reactions might prevent vascu-
lar tissue damage. During our search for compound(s) that
inhibit glycoxidation and lipoxidation reactions, we found
that 2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetani-
lide (OPB-9195) is a potent inhibitor for both glycoxidation
and lipoxidation reactions ([14,15], and manuscript submit-
ted). We therefore tested whether the inhibition of glycoxida-
tion and lipoxidation reactions by OPB-9195 prevents the de-
velopment of vascular lesions in rats following balloon injury
of their carotid arteries, a model exhibiting a remarkable in-
timal thickening.
2. Materials and methods
2.1. Human tissue specimens
Arterial tissue sections were obtained at autopsy from six (age 46^
56) non-diabetic patients with hypercholesteremia (s 250 mg/dl) and
ischemic heart diseases, such as myocardial infarction or angina, with
angiographic evidence of coronary artery disease and from 12 non-
diabetic patients with end-stage renal failure due to chronic glomer-
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ulonephritis who had undergone regular hemodialysis (seven males,
age range: 52^81 years old, hemodialysis duration range: 4^16 years).
The samples were ¢xed in 10% formalin and embedded in para⁄n.
2.2. Antibodies
Anti-pentosidine rabbit IgG [16], anti-HNE-protein adduct rabbit
IgG (kindly provided by Dr. K. Uchida) [17], and anti-MDA-lysine
mouse monoclonal IgG (kindly provided by Dr. J.L. Witztum) [18,19]
were used for immunohistochemistry. Anti-AGE rabbit IgG [20], the
major epitope-structure of which was identi¢ed as CML [20], was also
used.
2.3. Immunohistochemistry
Tissue sections (5 Wm thickness) were mounted on a slide coated
with 3-aminopropyltriethoxy silane (Sigma, St. Louis, MO), depara⁄-
nized, rehydrated in distilled water, and then incubated with either
anti-pentosidine, anti-AGE, anti-HNE-protein adduct, or anti-MDA-
lysine antibody overnight in humid chambers at room temperature.
The sections were washed and incubated with 1:100 diluted goat anti-
rabbit or -mouse IgG conjugated with peroxidase or alkaline phos-
phatase (Dako, Glostrup, Denmark) for 2 h, followed by the detection
with 3,3P-diaminobenzidine solution containing 0.003% H2O2 (for per-
oxidase) or with 5-bromo-4-chloro-3-indolyl phosphate and nitroblue
tetrazolium (for alkaline phosphatase). The speci¢city of immuno-
stainings was con¢rmed by competition experiments by incubating
anti-AGE, anti-pentosidine, anti-HNE, or anti-MDA antibody for
4 h at 37‡C with an excess of CML-, pentosidine-, MDA-, or
HNE-BSA, respectively, as described previously [16,20,21]. Non-
immune rabbit or mouse IgG was used as a negative control.
2.4. Experimental animals
Male 6-week-old normotensive, euglycemic Sprague-Dawley rats
weighing 180^200 g were used in studies conducted in accord with
the NIH Guide for the Care and Use of Laboratory Animals. Proto-
cols were approved by the Institutional Animal Care and Use Sub-
committee. The animals were housed under controlled temperature
and lighting conditions with access to food and water ad libitum.
Endothelial denudation and injury to the vascular wall were
achieved in the left common carotid artery of rats as described pre-
viously [22]. The rats were anesthetized with intraperitoneal adminis-
tration of sodium pentobarbital and Fogarty arterial embolectomy
balloon catheter (model 12-060-2F, Cv-1035: Baxter Health Care,
Santa Ana, CA) was inserted through the right iliac artery and ad-
vanced to left carotid artery via the aorta. The catheter was then
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Fig. 1. Immunohistochemical detection of glycoxidation and lipoxidation products in human atherosclerosis and uremic arteriosclerosis. Arterial
tissue specimens from a 55-year-old non-diabetic male (A^E) and from a 60-year-old non-diabetic uremic male who had undergone hemodialy-
sis for 11 years (F and G). Immunostaining for CD68 (A), CML (B and F), pentosidine (C), MDA-lysine (D and G), and HNE-protein adduct
(E). Nuclei were counterstained with Meyer’s hematoxylin. Glycoxidation and lipoxidation products are present in the proliferative intima
(B^G) and in macrophage-rich fatty streaks (B^E). A^E, U36; F and G, U18.
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in£ated with saline and gently withdrawn through the entire length of
the artery. After this procedure was repeated ¢ve times, the catheter
was removed, the wound was ligated and closed. The right carotid
artery remained untreated and served as an intraindividual control.
In order to evaluate the inhibitory e¡ect of OPB-9195 on intima
thickening, rats were given orally OPB-9195 suspended in 0.5% car-
boxymethyl cellulose sodium salt solution, twice daily (30 mg/kg of rat
weight) for 14 days following vascular injury. Control rats were given
orally the same amount of 0.5% carboxymethyl cellulose sodium salt
solution without OPB-9195.
Both carotid arteries were excised 14 days after the balloon injury,
adventitia removed with forceps, then washed three times in PBS.
Sections (10 mm length) proximal to the bifurcation of the carotid
arteries were ¢xed and sectioned for immunohistochemical analysis
and for light microscopy for morphometric analysis. The intimal/me-
dia ratio was measured as the ratio of the distance from the lumen to
the internal elastic lamina to the distance from the internal to the
external elastic lamina. The distances were measured by micrometry
on microscopic photographs of each vessel. Determinations were per-
formed on four di¡erent cross-sections of the vessel.
2.5. Statistical analysis
Data are expressed as means þ S.E.M. Student’s t-test was used for
a statistical evaluation of signi¢cant di¡erence between groups.
3. Results
3.1. Immunohistochemical detection of glycoxidation and
lipoxidation products in human atherosclerosis and
uremic arteriosclerosis
Early atherosclerosis is characterized by the di¡use intima
thickening and by fatty streaks composed primarily of multi-
ple layers of macrophage-derived foam cells. Fatty streaks
were stained positive for CD68 (Fig. 1A), i.e. macrophage-
derived foam cells. Both the glycoxidation products, CML
(Fig. 1B) and pentosidine (Fig. 1C), and lipoxidation prod-
ucts, MDA-lysine (Fig. 1D) and HNE-protein adduct (Fig.
1E), were stained positive in the proliferative intima and mac-
rophage-rich fatty streaks. Immunostainings were speci¢c as
demonstrated by their complete inhibition in the presence of
an excess of competitors (data not shown).
Uremic arteriosclerosis, characterized by the intimal thick-
ening of arterial walls, was then examined for glycoxidation
and lipoxidation products. Both glycoxidation and lipoxida-
tion products were stained positive in the proliferative intima
(exempli¢ed for CML, Fig. 1F and for MDA-lysine, Fig. 1G).
3.2. Inhibitory e¡ect of OPB-9195 on intimal thickening of rat
carotid artery following balloon injury
In order to test the e⁄cacy of OPB-9195 in the prevention
of vascular lesions, we utilized an experimental model of trau-
matic vascular lesion of the carotid artery in rats. Rat left
carotid arterial tissues obtained after balloon injury, exhibited
a remarkable intimal thickening (Fig. 2A), which is an early
and major event in the development of human vascular le-
sions, whereas the non-injured right carotid artery exhibited
no intimal thickening (Fig. 2B). The proliferative intima con-
tains glycoxidation and lipoxidation products: CML (Fig.
3A), pentosidine (Fig. 3B), MDA-lysine (Fig. 3C), and
HNE-protein adduct (Fig. 3D).
Daily oral administration of OPB-9195 in rats following
balloon injury markedly reduced intimal thickening in the
injured left carotid artery as shown in Fig. 2C and Table 1.
Immunohistochemical study revealed the positive stainings for
glycoxidation and lipoxidation products in the reduced intima
(data not shown). The non-injured right carotid artery of
OPB-9195-treated rats exhibited no intimal thickening (Fig.
2D).
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Fig. 2. Inhibitory e¡ect of OPB-9195 on intimal thickening of rat
carotid artery following balloon injury. Section of left carotid artery
(injured and non-treated with OPB-9195) showing the intimal re-
sponse 14 days after balloon injury (A). The e¡ect of OPB-9195
treatment on the left (injured and treated) vessel is shown in C.
Contralateral (non-injured) vessels in a rat without or with OPB-
9195 treatment are shown in B and D, respectively. Arrowsheads in-
dicate the internal elastic lamina. U16.
Fig. 3. Immunohistochemical detection of glycoxidation and lipoxi-
dation products in a rat carotid artery following balloon injury. Tis-
sue specimens from rat carotid artery 14 days after balloon injury.
Immunostaining for CML (A), pentosidine (B), MDA-lysine (C),
and HNE-protein adduct (D). Nuclei were counterstained with Mey-
er’s hematoxylin. Glycoxidation and lipoxidation products are
present in the intima. U35.
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4. Discussion
The immunohistochemical studies disclosed the co-distribu-
tion of protein adducts formed by glycoxidation and lipoxi-
dation reactions, not only in vascular lesions in aged subjects
(Fig. 1), but also in uremic patients (Fig. 2), in diabetic pa-
tients [14], and in a rat carotid artery following balloon injury
(Fig. 3). Our data are in agreement with previous studies by
others [23,24] demonstrating the presence of lipoxidation
products in atherosclerotic tissues. Therefore, the formation
of glycoxidation and lipoxidation products in vascular lesions
might be a phenomenon common in most if not all types of
vascular damage, irrespective of whether the stimulation of
vascular injury is metabolic or mechanical.
CML and pentosidine are combined products of glycation
and oxidation of proteins, whereas MDA-lysine and HNE-
protein adduct are oxidation-dependent lipid-protein adducts.
The antibodies used in the present study recognize distinct
structures, and apparently do not cross-react with the other
structures based on inhibition by modi¢ed BSA competitors
[16,20,21]. Therefore, the distribution of the four adducts,
which are formed on proteins with carbonyl compounds de-
rived from the oxidation of carbohydrates and lipids, in vas-
cular lesions provide independent evidence for a localized ox-
idative stress and carbonyl modi¢cation by glycoxidation and
lipoxidation reactions (‘carbonyl stress’).
Polyunsaturated fatty acids are undoubtedly the primary
sources of MDA-lysine and HNE-protein adduct. However,
the primary source of CML and pentosidine in vivo remains
inconclusive. In vitro incubation of BSA yielded pentosidine
from glucose and ascorbate, but not from arachidonate [14].
Of interest is our recent observation that in uremic patients,
the plasma levels of pentosidine were well correlated with
those of dehydroascorbate, but not with those of glucose
[11]. The primary source of CML in vivo is more complicated.
CML can be formed on BSA by incubation with glucose,
ascorbate, and arachidonate [14]. As previously suggested by
Fu et al. [12], CML in atherosclerotic fatty streaks in normo-
glycemic subjects could thus result not only from glycoxida-
tion reaction but also from lipoxidation reaction. In agree-
ment with this speculation, the plasma CML levels in
normoglycemic uremic patients on hemodialysis are correlated
with those of MDA-lysine, but not with those of fructosely-
sine, a marker of prevailing glucose concentration [25].
The present results that oral administration of OPB-9195
e¡ectively inhibited the intimal thickening of rat carotid artery
following balloon injury, suggests a link of carbonyl modi¢-
cation by glycoxidation and lipoxidation reactions to the de-
velopment of vascular lesions in rats. Whether it also applies
to humans remains to be investigated. OPB-9195 inhibits
most, if not all, carbonyl reactions with proteins including
not only glycoxidation but also lipoxidation reactions
([14,15], and manuscript submitted). A plausible explanation
for the inhibitory mechanism of OPB-9195 on the carbonyl
reactions might be the trapping of reactive carbonyl com-
pounds. The hydrazine nitrogen atom of OPB-9195 is capable
of reacting with carbonyl groups, directly or via the free base
upon hydrolysis, by the hydrazone formation. We therefore
speculate that OPB-9195 inhibits intimal thickening by en-
trapping reactive carbonyl compounds and quenching carbon-
yl reactions in vascular lesions. The reduced intima of injured
arterial walls in OPB-9195-treated rats still contained glyco-
xidation and lipoxidation products. The partial inhibitory ef-
fect of OPB-9195 on intimal thickening in the present model
thus might be ascribed to incomplete inhibition of carbonyl
reactions by OPB-9195.
However, other e¡ects of OPB-9195 independent of its ac-
tivity as carbonyl trap, e.g. inhibition of oxidative stress, re-
main to be examined. In this regard, recent studies demon-
strated that antioxidant butylated hydroxytoluene [26] or
probucol [27] treatment of hypercholesterolemic rabbits re-
duced intimal thickening after balloon injury.
Two possible mechanisms may be considered regarding the
role of carbonyl stress in vascular tissue damage. First, the
¢nal glycoxidation and lipoxidation products, such as AGEs,
have biological activities, e.g. stimulation of monocyte chemo-
taxis [3,28,29], secretion of in£ammatory cytokines from mac-
rophages [3,30,31], proliferation of vascular smooth muscle
cells [32], and quenching of nitric oxide activity [33]. Secondly,
as intermediate carbonyl compounds are capable of cross-
linking covalently with proteins, they might cross-link matrix
tissue or cell surface proteins, leading to alterations of struc-
ture and function of matrix proteins or stimulation of cellular
responses [34,35]. Indeed, exposure of murine thymocytes or
¢broblasts to carbonyl compounds, such as glyoxal, MDA, or
HNE, resulted in the phosphorylation of the tyrosine residues
of a number of intracellular proteins, which was completely
inhibited by pretreatment with OPB-9195 [36].
In conclusion, the present study suggests a link of increased
carbonyl modi¢cation by glycoxidation and lipoxidation reac-
tions to the development of vascular lesions. Further studies
will be undoubtedly required to evaluate the usefulness of
inhibitors of carbonyl reactions for the treatment of vascular
tissue damage.
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